TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 11.5M
Total Liabilities 11.5M
Shareholders Equity -114

Cash Flow Metrics

Revenue & Profitability Trend

Theraclion S.A Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i830.2K1.8M1.2M1.5M744.0K
Cost of Goods Sold i3.7M2.9M4.3M3.8M2.2M
Gross Profit i-2.9M-1.1M-3.1M-2.3M-1.5M
Gross Margin % i-346.0%-59.3%-246.9%-154.2%-201.9%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i-----
Other Operating Expenses i396.7K701.1K-54.6K-76.1K287.3K
Total Operating Expenses i396.7K701.1K-54.6K-76.1K287.3K
Operating Income i-6.8M-3.1M-6.3M-5.3M-4.2M
Operating Margin % i-819.6%-172.2%-507.7%-356.5%-569.3%
Non-Operating Items
Interest Income i7.0K30.8K---
Interest Expense i21.5K31.5K44.1K74.1K261.3K
Other Non-Operating Income-----
Pre-tax Income i-6.7M-4.7M-6.0M-5.5M-4.6M
Income Tax i-983.7K-1.0M-1.0M-882.6K-722.5K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-5.8M-3.7M-5.0M-4.6M-3.9M
Net Margin % i-693.5%-201.7%-401.8%-313.9%-524.9%
Key Metrics
EBITDA i-5.9M-2.4M-6.1M-5.3M-3.9M
EPS (Basic) i€-0.12€-0.08€-0.17€-0.17€-0.24
EPS (Diluted) i€-0.12€-0.08€-0.17€-0.17€-0.24
Basic Shares Outstanding i4626367045732250293876122276908516179830
Diluted Shares Outstanding i4626367045732250293876122276908516179830

Income Statement Trend

Theraclion S.A Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i4.2M7.8M2.5M2.5M2.3M
Short-term Investments i--31.1K31.1K31.1K
Accounts Receivable i267.8K3.1M2.2M1.2M1.4M
Inventory i2.1M3.1M3.1M2.6M2.2M
Other Current Assets-1-1-1-
Total Current Assets i8.3M16.1M9.3M7.9M7.0M
Non-Current Assets
Property, Plant & Equipment i1.7M128.1K177.6K45.5K952.6K
Goodwill i1.1M1.2M1.3M958.0K948.9K
Intangible Assets i1.1M1.2M1.3M958.0K948.9K
Long-term Investments-----
Other Non-Current Assets1.9K11.7K13.3K25.5K57.5K
Total Non-Current Assets i3.2M2.6M4.6M3.9M3.6M
Total Assets i11.5M18.7M13.9M11.8M10.5M
Liabilities
Current Liabilities
Accounts Payable i1.4M2.0M1.7M975.5K1.0M
Short-term Debt i----72
Current Portion of Long-term Debt-----
Other Current Liabilities791.1K504.5K674.6K796.8K799.4K
Total Current Liabilities i3.7M4.6M4.3M3.5M3.1M
Non-Current Liabilities
Long-term Debt i1.3M2.0M2.5M2.9M4.1M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities6.3M6.3M6.5M6.6M6.5M
Total Non-Current Liabilities i7.7M8.5M9.1M9.6M10.7M
Total Liabilities i11.5M13.0M13.4M13.1M13.8M
Equity
Common Stock i2.3M2.3M1.5M1.1M809.0K
Retained Earnings i-5.8M-3.7M-5.0M-3.8M-3.9M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-1145.6M544.9K-1.3M-3.2M
Key Metrics
Total Debt i1.3M2.0M2.5M2.9M4.1M
Working Capital i4.5M11.6M5.0M4.4M3.9M

Balance Sheet Composition

Theraclion S.A Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-5.8M-3.7M-5.0M-3.8M-3.9M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i0000-115.0K
Operating Cash Flow i-5.8M-3.7M-5.0M-3.7M-3.8M
Investing Activities
Capital Expenditures i-102.0K-112.0K-322.7K-148.2K-131.9K
Acquisitions i-----
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-102.0K-113.0K-322.7K-148.1K-131.9K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i----3.7M
Debt Repayment i-655.0K-784.0K-442.0K-1.2M-
Financing Cash Flow i-545.0K8.0M6.0M4.6M4.4M
Free Cash Flow i-3.0M-2.6M-5.6M-4.0M-3.5M
Net Change in Cash i-6.4M4.2M748.1K712.9K515.2K

Cash Flow Trend

Theraclion S.A Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -5.58
Forward P/E 6.58
Price to Sales 37.82
PEG Ratio 6.58

Profitability Ratios

Profit Margin -346.01%
Operating Margin -294.95%
Return on Equity -203.90%
Return on Assets -28.29%

Financial Health

Current Ratio 2.55
Debt to Equity -66,510.16
Beta -0.15

Per Share Data

EPS (TTM) €-0.10
Book Value per Share €0.00
Revenue per Share €0.02

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
althe31.4M-5.58--203.90%-346.01%-66,510.16
Guerbet S.A 293.8M18.030.733.50%1.89%100.91
Eurobio Scientific 251.9M64.361.412.26%2.58%5.46
Median Technologies 91.7M-1.84-74.31%-109.93%-0.98
Affluent Medical 60.0M-4.301.95-48.69%-275.50%0.54
Novacyt S.A 34.8M-0.800.70-57.28%-212.73%24.81

Financial data is updated regularly. All figures are in the company's reporting currency.